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Abstract
Background: The oxysterol 27-hydroxycholesterol (27-OHC) plays an important role in the regulation of cholesterol
homeostasis. Pregnancy pathologies like preeclampsia (PE), HELLP-syndrome (HELLP), intrauterine growth restriction
(IUGR) and intrahepatic cholestasis in pregnancy (ICP) are linked to disturbances in lipid metabolism. In the present
study, we hypothesized a specific gestational regulation of 27-OHC and compromised 27-OHC levels due to
placental and hepatic diseases in pregnancy resulting in a dysregulation of lipid metabolism.
Methods: The 27-OHC was measured by gas-chromatography-mass spectrometry (GC-MS) and related to cholesterol
concentrations. In the longitudinal cohort, a complete set of samples of healthy patients (n = 33) obtained at three
different time points throughout gestation and once post-partum was analyzed. In the cross sectional cohort, patients
with pregnancy pathologies (IUGR n = 14, PE n = 14, HELLP n = 7, ICP n = 7) were matched to a control group (CTRL) of
equal gestational ages.
Results: The 27-OHC levels already increased in the first trimester despite lower TC concentrations (p < 0.05). During
the course of pregnancy, a subtle rise in 27-OHC concentrations results in an overall decrease of 27-OHC/TC ratio in
between the first (p < 0.05) and second trimester. The ratio remains stable thereafter including the post-partum period.
No significant differences have been observed in pregnancy pathologies as compared to the CTRL group.
Conclusion: In conclusion, 27-OHC may have a compensatory role in cholesterol metabolism early in pregnancy. The
conserved 27-OHC/TC ratio in pregnancy pathologies suggest that neither the placenta nor the liver is majorly
involved in the regulation of 27-OHC metabolism.
Keywords: 27-hydroxycholesterol, 27-OHC/TC ratio, Preeclampsia, HELLP-syndrome, Intrauterine growth restriction,
Intrahepatic cholestasis in pregnancy, Lipid metabolism
Background
Cholesterol is an essential structural component of cell
membranes and is required to establish proper mem-
brane permeability and fluidity. In addition to its import-
ance within cells, cholesterol also serves as a precursor
for the biosynthesis of bile acids, vitamin D, and steroid
hormones. Thus, a tight regulation of cholesterol avail-
ability is crucial at each developmental stage in both, the
fetus and the mother. Human pregnancy is a state of
hyperlipidemia [1]. Maternal cholesterol concentrations
increase by 25 to 50%, thus contributing to the anabolic
state of the mother during pregnancy. Some pregnancy
pathologies are linked to disturbances in lipid metabol-
ism and cholesterol homeostasis. Women with intrahe-
patic cholestasis of pregnancy (ICP) show increased
cholesterol and LDL levels [2], while cholesterol and
LDL concentrations of women suffering from intrauter-
ine growth restriction (IUGR) are lower as compared to
gestational age matched controls (CTRL) [3]. Moreover,
preeclampsia (PE) has been regarded as a state of dyslip-
idemia with a prevalence of small dense LDL particles
and high triglyceride concentrations [4, 5].
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Oxysterols are mono-oxygenated metabolites of chol-
esterol and play an important role in the regulation and
maintenance of whole-body cholesterol homeostasis.
They participate in different aspects of lipid metabolism
and have been ascribed a number of roles in connection
with atherosclerosis, inflammation, apoptosis and im-
munosuppression [6, 7].
27-hydroxycholesterol (27-OHC) is the quantitatively
most dominating oxysterol in the circulation of human
adults [8]. It is produced upon hydroxylation of choles-
terol by the enzyme sterol 27-hydroxylase (CYP27A1)
[9]. In the liver, CYP27A1 catalyzes the first step of the
alternative bile acid pathway and intermediate step in
the classic bile acid pathway [10, 11]. In extra-hepatic
tissues, CYP27A1 has been implicated in cholesterol
efflux [12–14], the first and rate limiting step of reverse
cholesterol transport. Thus, the particularly high expres-
sion of CYP27A1 in vascular endothelial cells [15] and
macrophages [9] can be considered as a key element for
the removal of cholesterol excess. Loss of function muta-
tion in CYP27A1 leads to Cerebrotendinous Xanthoma-
tosis, a disease characterized by the absence of 27-OHC
and associated to early onset of atherosclerosis, despite
normal circulating plasma cholesterol concentrations.
In vitro, 27-OHC is a potent inhibitor of cholesterol
synthesis, as it acts as negative feedback regulator of the
HMGCoA-reductase, the rate limiting enzyme of cho-
lesterol biosynthesis [16]. Furthermore, 27-OHC is a
physiologically relevant endogenous agonist of the liver-
X-receptor (LXR), thereby governing the transcription of
genes involved in cholesterol catabolism, transport and
elimination [17, 18]. During pregnancy, oxysterols are
suggested to impair differentiation and invasion of
trophoblast cells via the LXR [19, 20].
Though 27-OHC has various physiological functions
that might influence pregnancy outcome, limited atten-
tion has been paid to concentration changes in pregnant
women so far. In the present study, we hypothesized a
specific gestational regulation of 27-OHC and compro-
mised 27-OHC levels due to different placental and
hepatic diseases in pregnancy resulting in a dysregula-
tion of lipid metabolism. We first aimed to measure the
cholesterol composition in serum throughout pregnancy
and post-partum (p.p.), and second to compare women
without and those suffering from gestational diseases
(ICP, PE, HELLP, IUGR). As suggested by Martin et al
1997, we related the 27-OHC concentrations to total chol-
esterol concentrations (TC) to adjust for inter-individual
variability and to get a proxy of CYP27A1 activity.
Methods
Ethical approval was obtained from the ethic committee
of the medical faculty of the Technical University of the
Rheinisch Westfälisch Technische Hochschule (RWTH)
Aachen (EK 138/06 19.06.2006, EK 119/08 02.09.2008, EK
154/11 19.07.2011). Written and informed consent was ob-
tained from each patient. Patients were recruited and serum
was sampled specifically to analyze biomarkers of preg-
nancy and pregnancy pathologies. Samples were aliquoted
and stored at the Aachen biobank at -80 °C till further use
(2006 to 2012). Sera to be analyzed were then chosen from
the biobank according to the following criteria.
In accordance with the ISSHP criteria [21] PE was
defined as new onset of hypertension >140/90 mmHg
after 20 weeks of gestation and proteinuria >300 mg/d
or at least 2+ in urine dip-stick.
IUGR was defined in accordance with the ACOG
guidelines [22]. The following criteria had to be fulfilled:
estimated fetal weight <10th percentile in addition to (i)
deceleration of fetal growth rate >40 percentiles in serial
measurements, (ii) elevated resistance index in umbilical
artery Doppler sonography above the 95th percentile,
or absent or reversed end diastolic blood flow, (iii)
fetal asymmetry (head-to-abdominal circumference ra-
tio >95th percentile), or (iv) oligohydramnios (amni-
otic fluid index <6 cm).
HELLP syndrome was defined as published recently
[23] as the presence of upper abdominal pain in accord-
ance with the confirmation of the following laboratory
criteria in maternal serum analyses: hemolysis (haptoglo-
bin levels <30 mg/dL), elevated liver enzyme activity
(AST, ALT, LDH) three standard deviations above the
mean, and platelet count <100.000 G/L.
ICP was defined as recently described by Mays et al.
2010 as the clinical finding of pruritus in combination
with an increased bile acid concentration in maternal
serum analysis >14 μmol/L, and elevated liver enzyme
activity (AST, ALT) above the reference values (>35 U/L)
[24] when HELLP syndrome was excluded.
Exclusion criteria for case and control groups were mul-
tiple gestation, abnormal fetal karyotype, fetal anomalies,
patients with clinical or biochemical signs of infection,
positive TORCH screening results, maternal diabetes
mellitus or other severe maternal metabolic disorders,
preterm birth following complications other than IUGR,
PE, or HELLP syndrome, and a patient’s withdrawal from
the study. Samples were taken from women prior to or at
least 5 days after administration of corticosteroids
(betamethasone) for induction of fetal lung maturity when
clinically indicated to avoid interference by steroid hor-
mone application to the mother.
Longitudinal cohort: Serum of 33 healthy patients, who
delivered after 37 weeks of gestation, was taken at three
different time points throughout gestation and at one time
point p.p. and analyzed by GC-MS (in total 132 samples).
The age range of participants in the longitudinal group
was from 21.5 to 48 years with a mean maternal age of
30.7 years.
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Cross sectional cohort: In the Aachen pregnancy
serum biobank, 7 patients were identified as ICP with an
age range from 22.5 to 38.1 years and a mean maternal
age of 25.8 years. 7 patients were classified as HELLP
with an age range from 27.4 to 43 years and a mean
maternal age of 32.4 years. 14 patients were IUGR with-
out hypertension (7 delivered before 34 weeks, 7 after
34 weeks) with an age range from 22.0 to 40.3 years and
a mean maternal age of 30.4 years. 14 patients were PE
without signs of IUGR (7 delivered before 34 weeks, 7
after 34 weeks) with an age range from 21.8 to 41.5 years
and a mean maternal age of 31.1 years. All of these
patients with complicated pregnancies were matched to
a control group (CTRL) of equal gestational ages con-
sisting of 42 women.
Lipid-analysis
The 27-OHC was measured in plasma (100-1000 μl) by
gas-chromatography-mass spectrometry (GC-MS) as
described previously [25] with 100 ng 5α-cholestan-
3β,6α-diol and 100 ng stigmasterol as standards. A
standard curve with increasing known concentrations was
performed for each extraction panel. Inter-assay variability
was controlled using an aliquot of plasma pool.
Serum lipid profile including triglycerides (TG), TC,
LDL-C and HDL-C was performed by colorimetric
enzymatic methods using an automated photometric
measuring unit (Roche/Hitachi Modular P800, Roche
Diagnostics, Basel, Switzerland; triglycerides GPO-PAP
reagent, cholesterol CHOD-PAP reagent, LDL-C plus
2nd generation reagent, HDL-C plus 3rd generation
reagent, Cobas®, Roche/Hitachi, Mannheim, Germany).
Measurement ranges were: TG = 4–1000 mg/dL, TC =
3–800 mg/dL, LDL-C = 3–550 mg/dL, and HDL-C =
3– 120 mg/dL.
Data analysis was carried out using the statistical
program Prism Version 5 Software (GraphPad Software
Inc., CA, USA). Clinical data are presented as means
and 95% confidence interval (95% CI) if metric. Correla-
tions were analyzed by Spearman’s correlation coeffi-
cient. Correlation coefficient values were considered
significant if p-value was <0.05. Kruskal-Wallis test
followed by Dunn’s comparison post hoc test was con-
ducted for comparison of measured variables between
the groups where indicated. Values of p < 0.05 were
regarded as significant.
Results
In the longitudinal cohort of 33 patients with uncompli-
cated pregnancies blood samples were obtained at 10+/-5,
27+/-5, and 37+/-3 weeks of gestation. A sample taken at
13+/-9 weeks p.p. represented non-pregnant control con-
ditions. Clinical characteristics and basic lipid profiles are
presented in Tables 1 and 2. Both 27-OHC levels and the
ratio of 27-OHC to TC throughout gestation and p.p. are
presented in Fig. 1. As compared to the first trimester
mean 27-OHC levels increased during pregnancy by 11%
in the second trimester and 18% in the third trimester and
dropped down by 8% p.p. (Fig. 1). Mean TC levels in-
creased by 63% from first to third trimester, followed by a
drop of 28% p.p.level (Table 2). TC p.p. was still higher
than during the first trimester (Table 2). The 27-OHC/TC
ratio, indicating apparent CYP27A1 activity, was 26%
higher in first trimester as compared to second and third
trimester and the p.p. state (Fig. 1).
The clinical characteristics and basic lipid profile of
the cross-sectional study groups are presented in Table 3.
Mean maternal age was similar in CTRL, PE, IUGR, and
ICP, while mothers with HELLP tended to be older.
About 20% of mothers in the IUGR group and in the
CTRL group smoked during pregnancy while none of
the patients in the other groups smoked. Mothers with
pregnancy pathologies gave birth earlier compared to
the CTRL group as indicated by the non-overlap of the
95% CIs. In the ICP group mothers were more likely to
deliver girls. Mean gestational ages of the study groups
at blood sampling were kept similar to the CTRL
counterparts.
The basic lipid profiles differed between the study
groups. As estimated by non-overlap of 95% CI TC and
LDL levels were lower in IUGR by 17% and 25%, respect-
ively, as compared to the CTRL group. A similar trend can
be observed in the HELLP syndrome. In ICP HDL levels
are 25% lower while LDL tended to be 37% higher as com-
pared to CTRL. We found a tendency of higher TG values
(+43%) in the PE group in comparison to CTRL.
Table 1 Clinical characteristics of the women with
uncomplicated pregnancy in the longitudinal cohort
Mean or % Lower
95% CI
Upper
95% CI
Maternal age (y) 30.7 28.7 32.7
Maternal BMI (kg/m2) 24.0 22.1 26.0
Primiparity (%) 85
Actual smoking status (%) 15
Mode of delivery (% c-section) 25
Fetal gender (% female) 55
WOG at delivery (w) 40.2 39.8 40.6
Neonatal birth weight (g) 3536 3380 3692
Neonatal weight percentile 50.5 41.7 59.2
Gestational age at first blood collection (w) 9.9 8.9 10.9
Gestational age at second blood
collection (w)
26.1 25.3 27.0
Gestational age at third blood collection (w) 36.5 36.0 37.0
Weeks post partum at blood collection (w) 12.5 20.6 4.5
WOG week of gestation
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TC-, 27-OHC- levels and 27-OHC/TC-levels ratios are
presented in Fig. 2. No significant differences were ob-
served between any of the study groups and the CTRL.
Nevertheless, 27-OHC tended to be higher in ICP (Fig. 2).
Discussion
In this study, we quantified for the first time the oxy-
sterol 27-OHC at different stages of gestation, analyzed
the impact of different diseases with placental dysfunc-
tion or maternal hepatic conditions and calculated the
27-OHC/TC ratio, a marker for CYP27A1 activity.
During pregnancy, lipid concentrations increase steadily
and pathologic pregnancies are associated with altered
lipid profiles. In this study, we quantified the oxy-
sterol 27-OHC, a hydroxylation product of cholesterol
by the enzyme CYP27A1. The amount of 27-OHC in-
creases throughout gestation and decreases p.p. to the
levels found in the first term of pregnancy. Interestingly,
the changes in 27-OHC are not exactly parallel to those
found in TC, as indicated by the 27-OHC/TC ratio. 27-
OHC concentrations are relatively higher than TC in first
trimester samples, while in later phases of gestation and
also p.p. both cholesterol levels were parallel to each
other. Based on our results, a relevant involvement of im-
paired CYP27A1 expression in pregnancy diseases associ-
ated with placental and hepatic dysfunction can be ruled
out. The amount of serum 27-OHC was not changed in
PE, IUGR and HELLP and was slightly increased in ICP.
Since the 27-OHC/TC ratio remains unchanged, a role for
impaired CYP27A1 activity can be excluded.
The expected potent biological activities of the oxysterol
27-OHC in cholesterol homeostasis are first to suppress
cholesterol biosynthesis by negative feedback regulation of
the rate-limiting enzyme of cholesterol biosynthesis,
3-hydroxy-3-methylglutaryl-coenzyme A reductase, and
second to provide an intermediate step in bile acids
biosynthesis, a major route for cholesterol elimination.
The production and the transport of 27-OHC from extra-
hepatic tissues to the liver might also be an alternative
pathway for reverse cholesterol transport based on HDL.
Weingartner suggested, that the production and the trans-
port of 27-OHC from extrahepatic tissues to the liver may
be an alternative pathway for reverse cholesterol transport
based on HDL [26]. Our results suggest an adaptation of
Table 2 Basic lipid profiles of the women with uncomplicated pregnancy in the longitudinal cohort
< 16 WOG 22 - 32 WOG > 34 WOG p.p.
Lipids Mean
or %
Lower
95% Cl
Upper
95% Cl
Mean
or %
Lower
95% CI
Upper
95% CI
Mean
or %
Lower
95% CI
Upper
95% CI
Mean
or %
Lower
95% CI
Upper
95% Cl
TC 165.3 154.2 174.2 245.7 230.5 260.9 268.8 254.8 282.8 204.9 189.8 220.0
LDL 83.39 74.78 92.01 139.9 126.2 153.6 154.5 140.6 168.3 116.7 105.2 128.2
HDL 59.15 54.61 63.70 77.85 71.90 83.79 71.30 65.47 77.14 62.85 57.51 68.19
TG 90.94 76.17 105.7 172.0 147.7 197.3 255.2 217.4 293.1 107.3 87.74 126.9
WOG week of gestation, TC total cholesterol, LDL low density lipoprotein, HDL high density lipoprotein, TG triglycerides
27OHC
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Fig. 1 27-OHC levels and the 27-OHC/TC-ratio throughout gestation and post-partum in the longitudinal cohort. As compared to the first trimester
mean 27-OHC levels increased during pregnancy by 11% in the second trimester and 18% in the third trimester and dropped down by 8% post-
partum. 27-OHC: 27-hydroxycholesterol. TC: total cholesterol. WOG: week of gestation. p.p.: post-partum. Correlations were analyzed by Spearman’s
correlation coefficient. Correlation coefficient values were considered significant if p-value was <0.05. Kruskal-Wallis test followed by Dunn’s comparison
post hoc test was conducted for comparison of measured variables between the groups where indicated. Values of p< 0.05 were regarded as significant
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CYP27A1 activity to increase the production of 27-OHC
in order to overcome the increased cholesterol concentra-
tions, even in ICP conditions. This observation highlights
that the liver is still able to synthesize 27-OHC. Addition-
ally, these results are in line with other reports suggesting
that 27-OHC production is preserved in patients with
liver diseases [27].
Of interest, 27-OHC levels already increase in the
first trimester despite lower TC concentration as a re-
sult of a high consumption and the luteo-placental
shift during early pregnancy [28]. This might either
be a compensatory mechanism to lower cholesterol
levels [8, 9], or a preparation for the upcoming high
cholesterol levels in later phases of pregnancy. It may
have additional regulatory roles as oxysterols have been
shown to affect trophoblast invasion via LXR-dependent
pathways [29] and hence potentially influence pregnancy
outcome.
With ongoing pregnancy, TC increases. This can be
attributed to increased cholesterol synthesis or a lower
cholesterol catabolism [30]. In our study, the increased
TC is accompanied by a subtle rise in 27-OHC concen-
trations, resulting in an overall decrease of the 27-OHC/
TC ratio from first to second trimester. This suggests
that 27-OHC is not necessarily involved in the inhibition
of cholesterol catabolism once pregnancy has reached
the second trimester. The ratio remains stable after the
first trimester until term and up to the post-partum
period, suggesting a highly balanced cholesterol-oxysterol
homeostasis throughout pregnancy.
Little is known about the concentrations of 27-OHC
during pregnancy pathologies. Moon et al. observed a
1.4 fold increase in 27-OHC concentrations in PE
compared to a control group while TC levels were 1.4
lower. Our results do not support a role for 27-OHC in
the pathomechanism of PE. Several reasons can be pro-
posed to explain these differences. First, Moon et al.
chose a control group consisting of patients that gave
birth preterm for other reasons than PE [31]. As preterm
birth per se has been linked to hyperlipidemia [32], this
– in our view – is not a reliable control group. Second,
there is often a mix with patients suffering from IUGR
in addition to PE. In our study, we have clearly separated
IUGR from the PE group. IUGR is associated with a de-
creased concentration of TC [33, 34]. Thus, it is conceiv-
able that in a subgroup of PE with IUGR TC may
decrease with increasing levels of 27-OHC. In the
present study, the 27-OHC/TC ratio was not different
between the IUGR and the CTRL group, respectively, at
the onset of the disease. Finally, the conflicting data
could simply be attributed to the higher body mass
index (in Moon’s study) or to the different genetic back-
ground of the study population.
In our study, pregnancies associated with placental in-
sufficiency like PE and IUGR were not associated with
alterations of 27-OHC levels, which may be explained by
the low expression of CYP27A1 in placenta. In the ICP
group with increased TC, 27-OHC was slightly but not
significantly increased. This rather indicates that
CYP27A1 is not impaired in this condition. As serum
bile acids are increased, we can only assume that the
classic pathway of bile acids initiated by CYP27A1 is
enhanced as protective mechanism to decrease TC.
Thus, the increased circulating TC in ICP can be
explained by enhanced hepatic cholesterol synthesis or
increased reverse cholesterol transport.
27-OHC
CT
RL PE
IU
GR
HE
LL
P
IC
P
0
100
200
300
400
ng
/m
L
27-OHC / TC
CT
RL PE
IU
GR
HE
LL
P
IC
P
0.0
0.5
1.0
1.5
ra
ti
o
Fig. 2 27-OHC levels and the 27-OHC/TC-ratio of women with gestational diseases in the cross-sectional study group. No significant differences
were observed between any of the study groups and the CTRL. CTRL: control group. PE: preeclampsia. IUGR: intrauterine growth restriction. ICP:
intrahepatic cholestasis in pregnancy. HELLP: hemolysis, elevated liver enzymes, low platelets syndrome. 27-OHC: 27-hydroxycholesterol. TC: total
cholesterol. Correlations were analyzed by Spearman’s correlation coefficient. Correlation coefficient values were considered significant if p-value
was <0.05. Kruskal-Wallis test followed by Dunn’s comparison post hoc test was conducted for comparison of measured variables between the
groups where indicated. Values of p < 0.05 were regarded as significant
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Strengths of this study are the evaluation of the time
course of 27-OHC and CYP27A1 activity during physio-
logical pregnancies and in non-pregnant conditions at
about 13 weeks p.p., combined with a cross-sectional
cohort for the investigation of pregnancy pathologies with
clearly defined subgroups and with an appropriate matched
control group. Additionally, we measured 27-OHC levels
at disease onset when most pronounced changes to normal
pregnancy would have been expected. It remains specula-
tion whether 27-OHC may play a role in the initiation of
pregnancy pathologies earlier in gestation. These results
have to be verified in a larger cohort of patients.
Conclusions
In conclusion, 27-OHC may play a compensatory role
in cholesterol metabolism early in pregnancy while
cholesterol-oxysterol-homeostasis is highly controlled
during the second and third trimester, and resembles the
non-pregnant situation. The conserved 27-OHC/TC ratio
in pregnancy pathologies suggests that neither an im-
paired placental function nor the change in hepatic func-
tion, as those found in ICP, account for the changes in
circulating 27-OHC concentrations. It is conceivable that
27-OHC plays a role in the regulation of the cholesterol
metabolism during early pregnancy. In late stages of preg-
nancy diseases, 27-OHC appears not to be altered. Yet, it
is still conceivable that in the first trimester, where oxy-
sterols may impact trophoblast invasion, placental vasore-
laxation and inflammation, a deranged 27-OHC could be
linked to the initiation of pregnancy pathologies. Hence,
further investigations are required with the focus on early
pregnancy before the manifestation of the disease.
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